Bloomberg Law Reports
Anti‐Commercial Bribery Laws in China and Their Enforcement in the Pharmaceutical Industry
November 2010
Anti‐commercial bribery laws have a huge impact on the daily business operation of companies in China. At present, relevant laws and regulations in China are very general and vague and, as a result, enforcement agencies at local levels have a great deal of discretion in determining what types of activities constitute commercial bribery, and what penalties will be imposed.
Contacts
Capabilities
Suggested News & Insights
Three Potential Benefits, One Powerful Incentive: NDIL’s New Individual Self-Disclosure ProgramMay 15, 2026New U.S. SEC Enforcement Director David Woodcock Signals Continued “Back to Basics” ApproachMay 14, 2026When “The Devil Made Me Do It” Is Not a Defense: Lessons in AI Governance and Organizational Oversight from an SDNY DecisionMay 13, 2026Sidley Ranked in Benchmark Litigation Asia-Pacific 2026May 13, 2026The First Prediction Market Insider Trading Case: SDNY and CFTC Test the Limits of Fraud and Commodities LawMay 13, 2026Sidley Represents Rigel Pharmaceuticals in Exclusive Global License Agreement with Pfizer and Arvinas for VEPPANUMay 13, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory